Q2 FY2026 EarningsQ2 FY2026 delivered a significant beat across all key financial metrics: net sales reached $872.3M (+13.8% YoY) vs. $839.98M expected, and adjusted diluted EPS was $2.37 (+28.8% YoY) vs. the $2.08 consensus. Growth was primarily fueled by the Proprietary Products segment, where organic sales rose 15.5% behind strong Biologics demand and GLP-1 elastomer growth. Management raised FY2026 revenue guidance to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05, signaling robust momentum for the remainder of the year.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: West Pharmaceutical(WST) the Revenue is 872.3 M (+13.8%), Beat estimate;the EBIT is 197.4 M (+27.11%), Beat estimate;the EPS is 2.15 (+18.13%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.87B13.80%
0.84B9.59%
+0.03B4.21%
EBITExceed expectations
0.20B27.11%
0.18B15.27%
+0.02B11.84%
EPSExceed expectations
2.1518.13%
2.07213.85%
+0.07804.28%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf